Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …

Thyroid cancer typically has a good outcome following standard treatments, which include
surgery, radioactive iodine ablation and treatment with TSH-suppressive levothyroxine …

Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial
stages their prognosis is excellent. However, few therapeutic options are available for …

The treatment of thyroid cancer has promising prospects, mostly through the use of surgical
or radioactive iodine therapy. However, some thyroid cancers, such as progressive …

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities
until recently. The extraordinary improvement in the comprehension of genetic and …

Context Many tyrosine kinase inhibitors (TKIs) have been studied in patients with thyroid
carcinoma (TC). However, the effect and toxicity of various TKIs in differentiated TC (DTC) …

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence
has been rising rapidly over the past 10 years. Although most patients with this disease have …

Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment
options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma …